Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naïve (AMBER) and virologically suppressed (EMERALD) participants with neurological and/or psychiatric comorbidities: Week 96 subgroup analysis.
Keith DunnJennifer BushenDonghan LuoJiyun CaiRichard Bruce SimonsonDavid AndersonPublished in: HIV medicine (2022)
D/C/F/TAF may be a suitable treatment option for individuals with HIV-1 and NPCs.